摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propionic acid | 1202690-20-7

中文名称
——
中文别名
——
英文名称
3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propionic acid
英文别名
3-[2,3-difluoro-4-(trifluoromethyl)phenyl]propanoic acid
3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propionic acid化学式
CAS
1202690-20-7
化学式
C10H7F5O2
mdl
——
分子量
254.156
InChiKey
HOSBDFQVCYVDGK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    硼烷3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propionic acid 在 3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propan-1-01 作用下, 生成 3-(2,3-difluoro-4-trifluoromethyl-phenyl)-propan-1-ol
    参考文献:
    名称:
    5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
    摘要:
    本发明涉及公式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物,其中R1、R2、R3和R4如描述中所述,以及其盐,特别是药学上可接受的盐,以及将这些化合物用作药物,特别是作为促进睡眠的药物。
    公开号:
    US20110105514A1
点击查看最新优质反应信息

文献信息

  • Novel pyrazolo-tetrahydropyridines as potent orexin receptor antagonists
    作者:Thierry Sifferlen、Christoph Boss、Emmanuelle Cottreel、Ralf Koberstein、Markus Gude、Hamed Aissaoui、Thomas Weller、John Gatfield、Catherine Brisbare-Roch、Francois Jenck
    DOI:10.1016/j.bmcl.2010.01.070
    日期:2010.3
    A novel series of dual orexin receptor antagonists was prepared by heteroaromatic five-membered ring system replacement of the dimethoxyphenyl moiety contained in the tetrahydroisoquinoline core skeleton of almorexant. Thus, replacement of the dimethoxyphenyl by a substituted pyrazole and additional optimization of the substitution pattern of the phenethyl motif allowed the identification of potent antagonists with low nanomolar affinity for hOX(1)R and hOX(2)R. The synthesis and structure-activity relationship of these novel antagonists will be discussed in this communication. These investigations furnished several suitable candidates for further evaluation in in vivo studies in rats. (C) 2010 Elsevier Ltd. All rights reserved.
  • [EN] 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS<br/>[FR] COMPOSÉS DE 5,6,7,8-TÉTRAHYDRO-IMIDAZO[1,5-A]PYRAZINE
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2009156951A2
    公开(公告)日:2009-12-30
    The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5- a]pyrazine derivatives of formula (I) wherein R1, R2, R3, and R4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
  • 5,6,7,8-TETRAHYDRO-IMIDAZO[1,5-A]PYRAZINE COMPOUNDS
    申请人:Aissaoui Hamed
    公开号:US20110105514A1
    公开(公告)日:2011-05-05
    The invention relates to 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives of formula (I) wherein R 1 , R 2 , R 3 , and R 4 are as described n the description, to salts, especially pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments; especially as orexin receptor antagonists.
    这项发明涉及式(I)的5,6,7,8-四氢咪唑[1,5-a]吡嗪衍生物,其中R1、R2、R3和R4如描述中所述,以及其盐,特别是药用可接受的盐,以及将这类化合物用作药物的用途;特别是作为促进睡眠的受体拮抗剂。
查看更多